TERNbenzinga

BMO Capital Maintains Outperform on Terns Pharma, Lowers Price Target to $15

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on May 13, 2025 by benzinga